EU/3/13/1151: Orphan designation for the treatment of malignant thymoma
Table of contents
On 17 July 2013, orphan designation (EU/3/13/1151) was granted by the European Commission to Topotarget A/S, Denmark, for belinostat for the treatment of malignant thymoma.
The sponsorship was transferred to Onxeo DK Filial af Onxeo S.A., Frankrig, Denmark, in June 2015.
Treatment of malignant thymoma
|Orphan designation status||
|EU designation number||
|Date of designation||
Onxeo DK, Filial af Onxeo S.A., Frankrig
2100 Copenhagen Ø
Tel. +45 3917 9494
Fax +45 3917 9492
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: